Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Clinical activity and benefit of irinotecan (CPT-11) in patients with metastatic colorectal carcinoma pre-treated with fluorouracil-based chemotherapy.

Tytuł :
Clinical activity and benefit of irinotecan (CPT-11) in patients with metastatic colorectal carcinoma pre-treated with fluorouracil-based chemotherapy.
Autorzy :
Ratanatharathorn V; Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand.
Sirachainan E
Jirajarus M
Sirilerttrakul S
Pokaż więcej
Źródło :
Journal of the Medical Association of Thailand = Chotmaihet thangphaet [J Med Assoc Thai] 2000 Oct; Vol. 83 (10), pp. 1187-95.
Typ publikacji :
Clinical Trial; Journal Article
Język :
English
Imprint Name(s) :
Original Publication: Bangkok : Medical Association Of Thailand
MeSH Terms :
Adenocarcinoma/*drug therapy
Adenocarcinoma/*secondary
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Camptothecin/*analogs & derivatives
Colorectal Neoplasms/*drug therapy
Palliative Care/*methods
Adult ; Aged ; Camptothecin/administration & dosage ; Camptothecin/adverse effects ; Colorectal Neoplasms/mortality ; Colorectal Neoplasms/pathology ; Drug Resistance ; Female ; Fluorouracil/administration & dosage ; Humans ; Infusions, Intravenous ; Irinotecan ; Male ; Middle Aged ; Prognosis ; Prospective Studies ; Severity of Illness Index ; Survival Rate ; Treatment Outcome
Substance Nomenclature :
7673326042 (Irinotecan)
U3P01618RT (Fluorouracil)
XT3Z54Z28A (Camptothecin)
Entry Date(s) :
Date Created: 20010106 Date Completed: 20010125 Latest Revision: 20181130
Update Code :
20210914
PMID :
11143484
Czasopismo naukowe
The purpose of this prospective study was to assess the efficacy, clinical benefit and safety of irinotecan (CPT-11) in patients with 5-fluorouracil-resistant metastatic colorectal cancer (CRC). Sixteen patients with World Health Organization (WHO) performance status < or = 2 were treated with CPT-11 350 mg/m2 every 3 weeks. The observed partial response (PR) rate was 6.3 per cent with a high rate of stable disease (SD) (43.7%) which was of long duration (21.1 weeks for the best response; 1PR, 7SD). The median survival time for the 16 patients entered into this study was 69.6 weeks. There was no toxic death. The most frequent adverse events were neutropenia (31% grade 3/4) and delayed diarrhea (9.7%). CPT-11 has definite activity in the treatment of progressive metastatic CRC truly resistant to 5-FU which translated into clinical survival benefit. Median survival from first administration of CPT-11 was 78.6 weeks for patients with best response (PR + SD) compared with 28.1 weeks for patients with progressive disease (PD) (P = 0.01). With the appearance of new active drugs in this highly chemotherapy-resistant disease, the definition of response should be reassessed in CRC.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies